Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention describes novel 1,3-dihydro-imidazol-2-one or 1,3-dihydro-imidazol-2-thione compounds of formula (I):
or a stereoisomer or pharmaceutically acceptable salt or solvate thereof, wherein A, L R1, R2, R3 and R4 are defined in the present specification, which are useful as selective inhibitors of MMP, TACE, aggrecanase or a combination thereof. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.
-
Citations
12 Claims
- 1. A compound of Formula (I):
-
6. A compound selected from the group:
-
4-(2-methyl-quinolin-4-yl methoxy)-N-[2-(2-oxo-2,3-dihydro-1H-imidazole-4-carbonyl)phenyl]benzamide; 4-(2-methyl-quinolin-4-yl methyl)-N-[2-(2-oxo-2,3-dihydro-1H-imidazole-4-carbonyl)phenyl]benzamide; 4-(2-methyl-quinolin-4-yl methoxy)-N-[2-(2-oxo-2,3-dihydro-1H-imidazol-4-yl methyl)phenyl]benzamide; 5-[4-(2-methyl-quinolin-4-ylmethoxy)-benzenesulfonylmethyl]-2-oxo-2,3-dihydro-1H-imidazole-4-carboxylic acid methyl ester; 4-[4-(2-methyl-quinolin-4-ylmethoxy)-phenylsulfanylmethyl]-1,3-dihydro-imidazol-2-one; 4-[4-(2-methyl-quinolin-4-ylmethoxy)-benzenesulfinylmethyl]-1,3-dihydro-imidazol-2-one; and 4-[4-(2-methyl-quinolin-4-ylmethoxy)-benzenesulfonylmethyl]-1,3-dihydro-imidazol-2-one; or a stereoisomer or pharmaceutically acceptable salt or solvate thereof. - View Dependent Claims (12)
-
Specification